Evidence from experiments performed in animal models and from early-stage clinical trials demonstrate that the contractile performance of hearts with severe ischemic injury can be improved by transplanting a variety of cell types into the injured heart.
Recently, we have adopted moderate hypothermic (≥25°C) circulatory arrest (MHCA) with antegrade cerebral perfusion (MHCA group). We compared the outcomes for these two circulatory arrest management strategies.
